Sunesis Pharmaceuticals, Inc. (SNSS): Price and Financial Metrics


Sunesis Pharmaceuticals, Inc. (SNSS): $18.62

3.64 (+24.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SNSS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SNSS Stock Price Chart Interactive Chart >

Price chart for SNSS

SNSS Price/Volume Stats

Current price $18.62 52-week high $24.80
Prev. close $4.28 52-week low $1.12
Day low $16.34 Volume 20,069,086
Day high $24.80 Avg. volume 4,330,995
50-day MA $2.73 Dividend yield N/A
200-day MA $2.59 Market Cap 336.89M

Sunesis Pharmaceuticals, Inc. (SNSS) Company Bio


Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company was founded in 1998 and is based in South San Francisco, California.


SNSS Latest News Stream


Event/Time News Detail
Loading, please wait...

SNSS Latest Social Stream


Loading social stream, please wait...

View Full SNSS Social Stream

Latest SNSS News From Around the Web

Below are the latest news stories about Sunesis Pharmaceuticals Inc that investors may wish to consider to help them evaluate SNSS as an investment opportunity.

Sunesis Pharmaceuticals, Owens & Minor leads healthcare gainers; Rafael, Constellation Pharmaceuticals among major losers

Gainers: Sunesis Pharmaceuticals (SNSS) +38%, Owens & Minor (OMI) +32%, Salarius Pharmaceuticals (SLRX) +20%, Poseida Therapeutics (PSTX) +20%, PRA Health Sciences (PRAH) +19%.Losers: Rafael (RFL) -12%, Constellation Pharmaceuticals (CNST) -12%, Biofrontera AG (BFRA) -10%, Celcuity (CELC) -9%, Tactile Systems Technology (TCMD) -7%....

Seeking Alpha | February 24, 2021

Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined, publicly traded company will focus on the advancement and expansion of Viracta's clinical stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma. Shares of the combined company, which is operating under the name Viracta Therapeutics, Inc., will commence trading on the Nasdaq Global Select Market under the ticker symbol "VIRX" on February 25, 2021.

Yahoo | February 24, 2021

Sunesis Pharma Climbs After Viracta Poised To Nab US Patent For Nanatinostat/Valganciclovir Regime

Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) merger partner, Viracta Therapeutics Inc announces that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," related to the use of Viracta's oral combination product candidate of nanatinostat and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial to treat Epstein-Barr virus (EBV)-associated lymphoma and other lymphoproliferative disorders. Upon its grant, the resulting patent will provide protection into at least 2040. In November last year, Sunesis Pharmaceuticals announced to merge with Viracta Therapeutics in an a...

Yahoo | February 16, 2021

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the treatment of Epstein-Barr virus (EBV)-associated lymphoma and other lymphoproliferative disorders. Upon its grant, the resulting patent will prov...

Yahoo | February 16, 2021

MERGER INVESTIGATION: Halper Sadeh LLP Investigates CPAH, HMSY, SNSS, EIDX; Shareholders Are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / January 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:CounterPath Corporation (NASDAQ:CPAH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Alianza, Inc. If you are a CounterPath shareholder, click here to learn more about your rights and options.

Yahoo | January 9, 2021

Read More 'SNSS' Stories Here

SNSS Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 39.23%
5-year -78.55%
YTD N/A
2021 0.00%
2020 -41.07%
2019 -18.82%
2018 -88.73%
2017 1.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6729 seconds.